SELATOGREL

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C28H39N6O8P
Molecular Weight	618.6184
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCCOC(=O)N1CCN(CC1)C(=O)[C@H](CP(O)(O)=O)NC(=O)C2=NC(=NC(=C2)N3CC[C@@H](C3)OC)C4=CC=CC=C4

InChI

InChIKey=FYXHWMQPCJOJCH-GMAHTHKFSA-N

InChI=1S/C28H39N6O8P/c1-3-4-16-42-28(37)33-14-12-32(13-15-33)27(36)23(19-43(38,39)40)30-26(35)22-17-24(34-11-10-21(18-34)41-2)31-25(29-22)20-8-6-5-7-9-20/h5-9,17,21,23H,3-4,10-16,18-19H2,1-2H3,(H,30,35)(H2,38,39,40)/t21-,23-/m0/s1

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25331625 | https://www.ncbi.nlm.nih.gov/pubmed/26550844 | https://www.pharmacodia.com/yaodu/html/v1/chemicals/a6334341d81fb047fb5dedb10148891a.html

ACT-281959 (molecular weight 850.9 g/mol), the di-ester prodrug of ACT-246475 (molecular weight 618.6 g/mol), was developed to improve absorption after oral dosing and is rapidly converted by esterases in vivo to ACT-246475 in two-steps via the formation of ACT-409100 (molecular weight 734.7 g/mol), the mono-ester prodrug. ACT-281959 is a novel potent and selective P2Y12 receptor antagonist with a wider therapeutic window. ACT-281959 showed antithrombotic efficacy after oral administration in the rat ferric chloride model. ACT-281959 entered clinical studies in healthy volunteers. ACT-281959 had been in phase I clinical trials by Actelion for the treatment of thrombosis. But there is no development reported for this study recently.

Originator

Approval Year

PubMed

Title	Date	PubMed
A new reversible and potent P2Y12 receptor antagonist (ACT-246475): tolerability, pharmacokinetics, and pharmacodynamics in a first-in-man trial.	2014 Nov	25331625
4-((R)-2-{[6-((S)-3-Methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carbonyl]amino}-3-phosphonopropionyl)piperazine-1-carboxylic Acid Butyl Ester (ACT-246475) and Its Prodrug (ACT-281959), a Novel P2Y12 Receptor Antagonist with a Wider Therapeutic Window in the Rat Than Clopidogrel.	2015 Dec 10	26550844

Sample Use Guides

In Vivo Use Guide

The study had a double-blind, randomized, ascending single-dose design with an oral formulation F1 (i.e., ACT-281959 or placebo) (Part I) and an open-label, randomized, 3-period, crossover design comparing exploratory formulations of ACT-281959 (F2) 70 mg and ACT-246475 (dF) 50 mg to F1 70 mg (Part II). In Part I, doses up to 1,000 mg were tested in 40 healthy subjects.

Route of Administration: Oral

Name

Type

Language

SELATOGREL

Official Name

English

1-PIPERAZINECARBOXYLIC ACID, 4-((2R)-2-(((6-((3S)-3-METHOXY-1-PYRROLIDINYL)-2-PHENYL-4-PYRIMIDINYL)CARBONYL)AMINO)-1-OXO-3-PHOSPHONOPROPYL)-, 1-BUTYL ESTER

Systematic Name

English

selatogrel [INN]

Common Name

English

4-((R)-2-((6-((S)-3-METHOXYPYRROLIDIN-1-YL)-2-PHENYLPYRIMIDINE-4-CARBONYL)AMINO)-3-PHOSPHONOPROPIONYL)PIPERAZINE-1-CARBOXYLIC ACID BUTYL ESTER

Systematic Name

English

ACT-246475

Code

English

Code System Code Type Description

PUBCHEM

59534142